If you are in the market for some new portfolio additions, it could be worth seeing what the team at Bell Potter is saying about the three ASX shares in this article. 

Does the broker rate them as buys, holds, or sells? Let’s find out:

Mesoblast Ltd (ASX: MSB)

Bell Potter notes that this biotechnology company released its quarterly update and revealed Ryoncil sales of US$28 million, which was well short of its forecast of US$40 million.

However, it points out that revenues were adversely impacted by low patient numbers across the summer months, with the low point in August.

As a result, the broker remains positive and has retained its buy rating on Mesoblast shares with a slightly trimmed price target of $4.40. It said:

The miss on September quarter revenues requires a downgrade to the forecast for FY27 Ryoncil revenues. The forecast is lowered by 18% ($243m to $203m) with the NPAT reduced by a similar quantum to $26.7m. The FY28 revenue forecast is reduced by 7%, however, there are no changes to the long-term outlook. Price target is reduced to $4.40.

PLS Group Ltd (ASX: PLS)

Bell Potter has also been looking at lithium giant PLS Group. It highlights that the company has announced plans to double Pilgangoora nameplate spodumene concentrate capacity to 2Mtpa. 

A feasibility study outlined development capex of $1.9 billion, with an incremental net present value (8% discount rate) of $2.7 billion.

In response, the broker has retained its buy rating on PLS shares with a trimmed price target of $4.10. It said:

While P2000 introduces medium-term execution risk, completion will meaningfully strengthen PLS’ long-term position as a large, low-cost hard-rock lithium producer. The company retains offtake optionality with ~50% of FY30 expected SC production of 2Mtpa uncontracted. Colina development studies are progressing, providing additional organic growth optionality in markets with strong underlying demand fundamentals from EV adoption and BESS deployment.

Seek Ltd (ASX: SEK)

The broker isn’t quite as positive on this job listings company’s shares. 

However, it was pleased to see that Seek’s job ad volume index slowed its annual rate of decline to -3.5% in September (Aug -5.3%). It also printed a third consecutive non-negative month on month number.

In response to the news, the broker has retained its hold rating on Seek shares with an improved price target of $13.60. It said:

We await a positive shift in sentiment or further visibility on jobs volumes recovery; potential near term Growth Fund monetisation remains an asymmetric upside risk, though the current interest rate backdrop may also be an additional headwind in seeking a desired exit price for nominated assets. 

SEK appears to be improving operations to sustainably target 10% yield growth on top of strong cost controls, however, despite trading at deep value ex. Growth Fund, macro-based headwinds suggest difficult sentiment near-term for the stock. Maintain Hold.

The post Buy, hold, sell: Mesoblast, PLS, and SEEK shares appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday
• Top brokers name 3 ASX shares to buy next week
• 3 ASX 200 mining shares to buy with 41% to 79% upside ahead: broker
• 9 ASX 200 shares experts are backing for growth amid market weakness

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are looking for new additions to your portfolio, then it could be worth listening to what analysts are saying about the top ASX shares named below, courtesy of The Bull. 

Here’s what they are recommending this week:

Ramelius Resources Ltd (ASX: RMS)

The team at Fairmont Equities thinks this gold miner could be an ASX share to buy this week.

It likes Ramelius Resources due to its belief that gold stocks will rally higher due to strong gold prices. It said:

Gold prices appear to have bottomed after trading much higher in early 2026. The share prices of various gold mining stocks have held up well, and this sign of strength is bullish. I’m expecting gold mining stock prices to rally higher from here as they follow potentially higher gold prices. 

RMS is an Australian gold producer with no debt and strong free cash flow. It pays a fully franked dividend and has been buying back shares. RMS is highly leveraged to an increasing gold price and the company’s outlook is bright.

Sigma Healthcare Ltd (ASX: SIG)

Over at Baker Young, it has named Chemist Warehouse owner Sigma Healthcare as an ASX share to buy.

Baker Young sees an opportunity for investors after recent share price weakness. It explains:

Sigma Healthcare is a wholesale distributer of pharmaceutical goods and medicines. Sigma merged with pharmaceutical retail giant Chemist Warehouse in 2025. The company’s share price has retreated to appealing entry levels at October 15. Its competitive position remains unrivalled, in our view. Structural health trends should continue to support organic growth. 

Although some competition is likely, the GLP-1 weight loss drug rollout should boost treatment sales. The Chemist Warehouse branded store network is forecast to generate double digit, like-for-like sales growth in full year 2027.

Xero Ltd (ASX: XRO)

Baker Young is also feeling positive about cloud accounting platform provider Xero and thinks it could be an ASX share to buy now.

It sees the material decline in the Xero share price as a buying opportunity for investors. Especially given its view that small to medium sized businesses will continue to use accounting and payment software rather than using AI to develop their own systems. It explains:

Xero is an accounting software provider. Concerns about future growth rates due to perceived competitive threats from AI tools remain. But we believe the material decline in XRO’s share price amid the company continuing to deliver operational performance inline or above market guidance has created a compelling value opportunity. 

We believe small to medium sized firms handling critical financial information will continue using trusted third party suppliers rather than develop their own systems. XRO’s strong growth rates justify higher than average multiples, in our view. We’re comfortable building positions for longer term investors around current levels.

The post Experts name 3 top ASX shares to buy this week appeared first on The Motley Fool Australia.

More reading

• How much could the Sigma Healthcare share price rise in the next year?
• ASX 200 utilities and healthcare shares win the week again
• Why these are my favourite ASX growth shares to buy and hold
• 9 ASX 200 shares experts are backing for growth amid market weakness
• I investigated 3 ASX shares that have fallen sharply. Are they bargains or value traps?

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) ascended 1% last week and is down 2.5% over 12 months.

Let’s start the week with some new ratings from market experts (courtesy The Bull). 

JB Hi Fi Ltd (ASX: JBH)

The JB Hi-Fi share price has tumbled 37% over 12 months.

Andrew Wielandt from DP Wealth Advisory has a buy call on this ASX 200 consumer discretionary share. 

Wielandt said: 

This consumer electronics giant continues to show why it’s one of Australia’s highest quality retailers.

The company delivered record total sales of $11.06 billion in full year 2026, up 4.8 per cent on the prior corresponding period.

Net profit after tax of $489.9 million increased 6 per cent. The total fully franked dividend of $3.37 was up 22.5 per cent.

The company continues to take market share through its low cost operating model, strong brand recognition and leadership across consumer electronics.

Our recommendation is supported by a proven management team, strong cash generation and a history of executing well during varying economic conditions.

Sandfire Resources Ltd (ASX: SFR)

The Sandfire Resources share price is up 31% over 12 months. 

Michael Gable from Fairmont Equities has a hold rating on this ASX 200 copper share. 

Gable said: 

SFR is Australia’s largest listed pure play copper producer. Copper demand is increasing in an environment of low supply and this is likely to lead to higher prices.

Group sales revenue of $1.7 billion in full year 2026 was up 41 per cent year on year. Profit after tax of $354 million was up 294 per cent.

Its final fully franked dividend of 35 cents a share was much higher than the market was expecting.

From a charting perspective, the price action for SFR looks bullish and we expect to see a sustainable uptrend from here.

Ramsay Health Care Ltd (ASX: RHC)

The Ramsay Health Care share price has streaked 77% higher over 12 months.

Toby Grimm from Baker Young has a sell rating on this ASX 200 healthcare share. 

Grimm explained: 

Ramsay Health Care is one of the largest private hospital operators in Australia. It has additional operations in the UK and Europe.

Ramsay’s operations have improved. Insurer pricing better reflects cost inflation, with higher demand and higher margin procedures prioritised.

Yet the industry remains challenging and public sector competitors effectively set input costs without needing to operate profitably.

The stock has strongly rallied in the past 12 months to the point we believe it’s exposed to a pullback.

The forward price/earnings ratio has risen significantly above its 10-year average.

Investors may want to consider booking profits and monitor performance from the sidelines.

The post Buy, hold, sell: JB Hi-Fi, Sandfire Resources, Ramsay Health Care shares appeared first on The Motley Fool Australia.

More reading

• 6 ASX shares hit by broker downgrades this week
• Own ASX mining shares? Official forecasts show commodity prices peaking in FY27
• 2 top ASX blue-chip shares to buy according to experts
• Buy, hold, sell: Wildcat Resources, Ramsay Health Care, CBA shares
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.